Evidence map›Paper›PMID 35697880›Full record

ArticleActa neuropathologica2022

Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts.

Peter T Nelson, Carol Brayne, Margaret E Flanagan, Erin L Abner, Sonal Agrawal, Johannes Attems, Rudolph J Castellani, Maria M Corrada, Matthew D Cykowski, Jing Di and 39 more

Open access · greenAbstract read
In one paragraph

Article in Acta neuropathologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
133citing papers in PubMed, 1 pooled it
21.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

133 citing papers in PubMed, 1 synthesis or guideline pooled it, 153 citations in OpenAlex.

  1. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Distinct single-nucleus RNA-seq changes among non-neuronal cells in ADNC, LATE-NC, and mixed pathologies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Article
  7. Article
  8. Hormone replacement therapy and its association with LATE-NC in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  9. Brain morphometry patterns in the presence of Alzheimer's disease and/or LATE neuropathologic changes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Neuropathology in a diverse cohort of oldest-old: The LifeAfter90 study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  16. Article
  17. Hippocampal GFAP in aging: Associations with AD and LATE-NC pathologies and cognitive decline in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  18. Article
  19. Review
  20. Article

73 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

49 authors at 20 institutions in 7 countries.

Peter T NelsonUniversity of Kentucky, Rm 311 Sanders-Brown Center on Aging, Lexington, KY, USA. pnels2@email.uky.edu.
Carol BrayneUniversity of Cambridge, Cambridge, UK.
Margaret E FlanaganNorthwestern University Medical Center, Chicago, IL, USA.
Erin L AbnerUniversity of Kentucky, Rm 311 Sanders-Brown Center on Aging, Lexington, KY, USA.
Sonal AgrawalRush University Medical Center, Chicago, IL, USA.
Johannes AttemsNewcastle University, Newcastle upon Tyne, UK.
Rudolph J CastellaniNorthwestern University Medical Center, Chicago, IL, USA.
Maria M CorradaUniversity of California, Irvine, CA, USA.
Matthew D CykowskiHouston Methodist Hospital, Houston, TX, USA.
Jing DiUniversity of Kentucky, Rm 311 Sanders-Brown Center on Aging, Lexington, KY, USA.
Dennis W DicksonMayo Clinic, Jacksonville, FL, USA.
Brittany N DuggerUniversity of California, Davis, CA, USA.
John F ErvinDuke University, Durham, NC, USA.
Jane FlemingUniversity of Cambridge, Cambridge, UK.
Jonathan Graff-RadfordMayo Clinic, Rochester, MN, USA.
Lea T GrinbergUniversity of California, San Francisco, CA, USA.
Suvi R K HokkanenUniversity of Cambridge, Cambridge, UK.
Sally HunterUniversity of Cambridge, Cambridge, UK.
Alifiya KapasiRush University Medical Center, Chicago, IL, USA.
Claudia H KawasUniversity of California, Irvine, CA, USA.
Hannah A D KeageUniversity of South Australia, Adelaide, SA, Australia.
C Dirk KeeneUniversity of Washington, Seattle, WA, USA.
Mia KeroUniversity of Helsinki and Helsinki University Hospital, Helsinki, Finland.
David S KnopmanMayo Clinic, Rochester, MN, USA.
Naomi KouriMayo Clinic, Jacksonville, FL, USA.
Gabor G KovacsTanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, ON, Canada.
Sydney A LabuzanMayo Clinic, Jacksonville, FL, USA.
Eric B LarsonKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Caitlin S LatimerUniversity of Washington, Seattle, WA, USA.
Renata E P LeiteUniversity of Sao Paulo Medical School, Sao Paulo, Brazil.
Billie J MatchettMayo Clinic, Jacksonville, FL, USA.
Fiona E MatthewsNewcastle University, Newcastle upon Tyne, UK.
Richard MerrickUniversity of Cambridge, Cambridge, UK.
Thomas J MontineStanford University, Stanford, CA, USA.
Melissa E MurrayMayo Clinic, Jacksonville, FL, USA.
Liisa MyllykangasUniversity of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Sukriti NagRush University Medical Center, Chicago, IL, USA.
Ruth S NelsonEmory University, Atlanta, GA, USA.
Janna H NeltnerUniversity of Kentucky, Rm 311 Sanders-Brown Center on Aging, Lexington, KY, USA.
Aivi T NguyenMayo Clinic, Rochester, MN, USA.
Ronald C PetersenMayo Clinic, Rochester, MN, USA.
Tuomo PolvikoskiNewcastle University, Newcastle upon Tyne, UK.
R Ross ReichardMayo Clinic, Rochester, MN, USA.
Roberta D RodriguezUniversity of Sao Paulo Medical School, Sao Paulo, Brazil.
Claudia K SuemotoUniversity of Sao Paulo Medical School, Sao Paulo, Brazil.
Shih-Hsiu J WangDuke University, Durham, NC, USA.
Stephen B WhartonSheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
Lon WhitePacific Health Research and Education Institute, Honolulu, HI, USA.
Julie A SchneiderRush University Medical Center, Chicago, IL, USA.
Mayo Clinic in Arizona · USUniversity of Cambridge · GBRush University Medical Center · USUniversidade de São Paulo · BRUniversity of Kentucky · USNewcastle University · GBWinnMed · USDuke University · USMayo Clinic in Florida · USUniversity of California, Irvine · USUniversity of Washington · USEmory University · USHelsinki University Hospital · FIKaiser Permanente Washington Health Research Institute · USMethodist Hospital · USNorthwestern University · USOccupational Cancer Research Centre · CAPacific Health Research and Education Institute · USStanford University · USUniversity Medical Center · US

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Translational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI CHRISTOPHER DIRK KEENE · 2021 to 2026
$80.4M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
Project 4 (Genetic modifiers for APOE-associated Alzheimer's disease pathogenesis)U19AG069701 · NIA · MAYO CLINIC JACKSONVILLE · PI Celeste Marie Karch · 2021 to 2026
$42.0M
Diversity Supplement to R01AG021055; Clinical, Imaging, and Pathological Studies in the Oldest Old: The 90+ StudyR01AG021055 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI CORRADA, MARIA, KAWAS, CLAUDIA H. · 2002 to 2024
$36.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Thomas J. Grabowski · 2020 to 2026
$29.0M
The Alzheimer's Disease Research Center at the University of California, IrvineP30AG066519 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Elizabeth Head · 2020 to 2026
$27.9M
Research Education Core FP30AG072977 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SANDRA WEINTRAUB · 2021 to 2026
$26.3M
UC Davis Alzheimer's Disease Research CenterP30AG072972 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Charles DeCarli, Rachel A Whitmer · 2021 to 2026
$25.2M
Rush Alzheimer's Disease Research CenterP30AG072975 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI Lisa L Barnes, Julie A. Schneider · 2021 to 2026
$24.7M
Medical Research Council G0601022Medical Research Council G0900582Medical Research Council G9901400Medical Research Council MRC/G0900582Medical Research Council MRC/G9901400Medical Research Council U.1052.00.0013NIA NIH HHS K08 AG065426NIA NIH HHS K08 AG065463NIA NIH HHS K24 AG053435NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072975NIA NIH HHS P30 AG072977NIA NIH HHS R01 AG021055NIA NIH HHS R01 AG022018NIA NIH HHS R01 AG034676NIA NIH HHS R01 AG038651NIA NIH HHS R01 AG054449NIA NIH HHS R01 AG057187NIA NIH HHS R01 AG061111NIA NIH HHS R01 AG062517NIA NIH HHS R01 AG064233NIA NIH HHS R01 AG067482NIA NIH HHS R33 AG058738NIA NIH HHS RF1 AG069052NIA NIH HHS RF1 AG072080NIA NIH HHS U01 AG006786NIA NIH HHS U19 AG066567NIA NIH HHS U19 AG069701NIA NIH HHS U24 AG021886NIA NIH HHS UF1 AG057707NINDS NIH HHS RF1 NS118584NINDS NIH HHS UF1 NS125417
6 · The paper itself

Abstract

Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) and Alzheimer's disease neuropathologic change (ADNC) are each associated with substantial cognitive impairment in aging populations. However, the prevalence of LATE-NC across the full range of ADNC remains uncertain. To address this knowledge gap, neuropathologic, genetic, and clinical data were compiled from 13 high-quality community- and population-based longitudinal studies. Participants were recruited from United States (8 cohorts, including one focusing on Japanese-American men), United Kingdom (2 cohorts), Brazil, Austria, and Finland. The total number of participants included was 6196, and the average age of death was 88.1 years. Not all data were available on each individual and there were differences between the cohorts in study designs and the amount of missing data. Among those with known cognitive status before death (n = 5665), 43.0% were cognitively normal, 14.9% had MCI, and 42.4% had dementia-broadly consistent with epidemiologic data in this age group. Approximately 99% of participants (n = 6125) had available CERAD neuritic amyloid plaque score data. In this subsample, 39.4% had autopsy-confirmed LATE-NC of any stage. Among brains with "frequent" neuritic amyloid plaques, 54.9% had comorbid LATE-NC, whereas in brains with no detected neuritic amyloid plaques, 27.0% had LATE-NC. Data on LATE-NC stages were available for 3803 participants, of which 25% had LATE-NC stage > 1 (associated with cognitive impairment). In the subset of individuals with Thal Aβ phase = 0 (lacking detectable Aβ plaques), the brains with LATE-NC had relatively more severe primary age-related tauopathy (PART). A total of 3267 participants had available clinical data relevant to frontotemporal dementia (FTD), and none were given the clinical diagnosis of definite FTD nor the pathological diagnosis of frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). In the 10 cohorts with detailed neurocognitive assessments proximal to death, cognition tended to be worse with LATE-NC across the full spectrum of ADNC severity. This study provided a credible estimate of the current prevalence of LATE-NC in advanced age. LATE-NC was seen in almost 40% of participants and often, but not always, coexisted with Alzheimer's disease neuropathology.

Indexed as

Alzheimer DiseaseFrontotemporal DementiaNervous System DiseasesAged, 80 and overAmyloidAutopsyDNA-Binding ProteinsHumansMalePlaque, AmyloidAmyloidDNA-Binding ProteinsACTADRDAPOEBiobank for aging studiesCC75CCFASEpidemiologyHAASMayo clinic study of agingNFTNondementedNun studyOldest-oldROS-MAPTauThe 90 + studyVantaa 85 +VITA

Identifiers

PMID35697880
PMCPMC9552938
OpenAlexW4282596629

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.